Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition by Nielsen, Stine E. et al.
Tubular and Glomerular Injury in Diabetes
and the Impact of ACE Inhibition
STINE E. NIELSEN, MD
1
TAKESHI SUGAYA, MD, PHD
2
LISE TARNOW, MD, DMSC
1
MARIA LAJER, CANDSCI
1
KATRINE J. SCHJOEDT, MD
1
ANNE SOFIE ASTRUP, MD
1
TSUNEHARU BABA, MD, PHD
3
HANS-HENRIK PARVING, MD, DMSC
4
PETER ROSSING, MD, DMSC
1
OBJECTIVE — We studied tubular and glomerular damage in type 1 diabetic patients by
measuring urinary–liver fatty acid binding protein (U-LFABP) and albuminuria. Subsequently,
we evaluated the effect of ACE inhibition on U-LFABP in patients with diabetic nephropathy.
RESEARCHDESIGNANDMETHODS — WestudiedCaucasianswithtype1diabetes:
58 with normoalbuminuria (urinary albumin 30 mg/24 h), 45 with persistent microalbumin-
uria (30–300 mg/24 h), and 45 with persistent macroalbuminuria (300 mg/24 h). A control
group consisted of 57 healthy individuals. The groups were matched by sex and duration of
diabetes. In addition, U-LFABP was measured in 48 type 1 diabetic patients with diabetic
nephropathy in a randomized crossover trial consisting of 2 months of treatment with 20, 40,
and 60 mg lisinopril once daily in random order.
RESULTS — In the cross-sectional study, levels of U-LFABP were signiﬁcantly higher in
normoalbuminuric patients versus those in the control group (median 2.6 [interquartile range
1.3–4.1] vs. 19 [0.8–3.0] g/g creatinine, P  0.02) and increased with increasing levels of
albuminuria (microalbuminuric group 4.2 [1.8–8.3] g/g creatinine and nephropathy group
71.2 [8.1–123.4], P  0.05 for all comparisons). U-LFABP correlates with the urinary albumin-
to-creatinine ratio (R
2  0.54, P  0.001). In the intervention study, all doses of lisinopril
signiﬁcantlyreducedurinaryalbuminexcretionrateandU-LFABPfrombaseline.Thereductions
in U-LFABP were 43, 46, and 40% with increasing doses of lisinopril (NS).
CONCLUSIONS — An early and progressive increase in tubulointerstitial damage as re-
ﬂected by increased U-LFABP levels occurs in type 1 diabetic patients and is associated with
albuminuria. Furthermore, ACE inhibition reduces the tubular and glomerular damage and
dysfunction.
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D
iabeticnephropathyisaseriousand
common complication in diabetic
patients. Although studies from se-
lected centers suggest a declining inci-
dence of diabetic nephropathy (1), still
30–40% of all patients with diabetes de-
velop this complication (2). Diabetic ne-
phropathy is associated with a higher risk
of other complications such as cardiovas-
cular disease, retinopathy, and neuropa-
thy. It is the most common cause of end-
stage renal failure in Western countries.
Therefore, it is of great interest to predict
and prevent the development of diabetic
nephropathy.
Persistentmicroalbuminuriaisthees-
tablished predictor of development of di-
abetic nephropathy and progressive renal
insufﬁciency.However,useoftheurinary
albumin excretion rate (UAER), as an in-
dicator of renal damage, has some lim-
itations. Several patients with
microalbuminuria do not progress to
macroalbuminuria but continue having
microalbuminuria (30%) or even regress
to normoalbuminuria (15–30% after 7.5
years of follow-up) (3). As reviewed pre-
viously, glomerular damage and tubulo-
interstitial damage are important factors
in the pathology of diabetic nephropathy
(2,4).
Liver fatty acid binding protein
(LFABP) is an intracellular carrier protein
that is expressed in the proximal tubules
in the human kidney and the liver (5). By
immunohistochemical staining of renal
biopsy specimens, it has been shown that
urinary LFABP (U-LFABP) excretion is
highly associated with structural and
functional tubular kidney damage. This
was conﬁrmed in patients with chronic
kidneydiseaseincludingminimal-change
nephritic syndrome, nephrosclerosis, lu-
pus nephritis, and diabetic nephropathy
(6). A previous study in chronic kidney
disease has shown that serum LFABP lev-
elsdonotaffecttheU-LFABPlevel,which
suggests that there is no transglomerular
passage of LFABP in chronic kidney dis-
ease and that the LFABP measured in
urine originates primarily from tubular
cells (7). It has been hypothesized that
LFABP is a protective protein; however,
previous studies have, to our knowl-
edge, not been able to conﬁrm this
hypothesis (8).
In patients with diabetic nephropathy,
a reduction in albuminuria is a predictor
of renoprotection (9). It is suggested that
the combination of the two parameters,
albuminuriaandU-LFABP,wouldbeuse-
ful in monitoring chronic kidney disease
more than either alone.
The relationship between albumin-
uriaandU-LFABPhas,toourknowledge,
not been studied in type 1 diabetic pa-
tients. Furthermore, whether U-LFABP
could be used to monitor the renoprotec-
tive effect on the decline in glomerular
ﬁltration rate (GFR) or the effect on uri-
nary albumin excretion in short-term
studies in type 1 diabetic patients with
diabetic nephropathy has not been
studied.
The aim of this study was to investi-
gate the levels of U-LFABP in a cross-
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with different levels of albuminuria com-
pared with those in a nondiabetic control
group. In addition, we wanted to explore
the short-term effect of increasing doses
of the ACE inhibitor lisinopril on U-
LFABP levels in patients with type 1 dia-
betes and diabetic nephropathy from a
randomized, double-blind crossover
study.
RESEARCH DESIGN AND
METHODS— The cross-sectional
study was based on data from a cohort
used to identify biomarkers of diabetic
nephropathy by proteomic analyses (10).
The population consisted of Caucasian
patientswithtype1diabetesanddifferent
levels of albuminuria recruited from the
outpatient clinic at Steno Diabetes Center
in 2004. Based on albumin excretion in
24-h urine samples that were collected as
part of the routine care of the patients be-
fore the present study, patients were di-
vided into three groups: 58 with
normoalbuminuria (UAER 30 mg/24
h), 45 with persistent microalbuminuria
(UAERbetween30and300mg/24hinat
least two of three consecutive samples)
and45withpersistentmacroalbuminuria
(UAER 300 mg/24 h in at least two of
three consecutive samples). The control
group consisted of 57 nondiabetic
healthy individuals. The 24-h urine sam-
ples were only used for assessing inclu-
sioncriteria.Groupswerematchedbysex
and duration of diabetes.
Investigations were performed in the
morning. Arterial blood pressure was mea-
suredthreetimeswithanappropriate-sized
cuff after at least a 10-min rest. Urinary al-
buminconcentrationwasmeasuredbyan
enzyme immunoassay from early morn-
ing spot urine samples and expressed as
the urinary albumin-to-creatinine ratio
(UACR). Serum and urine creatinine con-
centrations were assessed by a kinetic
Jaffe ´ method. Estimated GFR (eGFR) was
calculated using the reexpressed four-
variableModiﬁcationofDietinRenalDis-
ease study equation (eGFR  175 
plasma creatinine
1.154  age
0.203 
1.212 [if black] or  0.742 [if female]) as
deﬁnedpreviously(11)whereeGFRisex-
pressed as milliliters per minute per 1.73
m
2 and plasma creatinine is expressed as
milligrams per deciliter. U-LFABP was
measured in a two-step sandwich en-
zyme-linked immunosorbent assay (12)
and expressed as the U-LFABP-to-
creatinineratio.Theinter-andintra-assay
variations were 6.8 and 8.2%, respec-
tively. Plasma samples were stored at
80°C, and urine samples were stored at
20°C until analysis.
The second study was a randomized
double-masked crossover trial performed
in2005(13).Patientsweretreatedinran-
dom order with 20, 40, and 60 mg lisin-
opril, with each period lasting 2 months.
Atotalof56patientswithtype1diabetes,
hypertension (135/85 mmHg), and di-
abetic nephropathy were randomly as-
signed in the study.
The primary end point was changes
in UAER (micrograms per 24 h). Albu-
minuria was determined in three consec-
utive 24-h urine collections completed
immediately before the end of each treat-
ment period. Among the secondary end
points measured at the end of each treat-
ment period were 24-h ambulatory blood
pressure and eGFR. U-LFABP was also
measured in 24-h urine collections (mi-
crograms per 24 h). For safety reasons,
blood pressure, plasma potassium,
plasma sodium, and plasma creatinine
were determined 3 weeks after the begin-
ningofeachtreatmentperiod.GFR(base-
line) was measured at baseline after a
single intravenous injection of 3.7 MBq
51Cr-EDTA at 8:30 A.M. by determining
the radioactivity in venous blood samples
taken 180, 200, 220, and 240 min after
injection. The results were standardized
for1.73m
2bodysurfacearea.Bloodpres-
sure was measured by a 24-h ambulatory
blood pressure device (Takeda TM2421;
A & D Medical, Tokyo, Japan).
The study was initiated by a 2-month
washout period during which all antihy-
pertensive drugs were withdrawn, except
for slow-release furosemide in individual
doses to prevent ﬂuid retention and hy-
perkalemia and control blood pressure.
Thereafter, patients were treated in ran-
dom order with 20, 40, and 60 mg lisino-
pril, with each period lasting 2 months.
Dietary intake of protein and salt was not
restricted.
Both studies were performed accord-
ing to the principles of the Declaration of
Helsinki and the intervention study was
approved by the ethics committee of
Copenhagen County. Written informed
consent was obtained from all patients.
Statistical analysis
Normally distributed variables are ex-
pressed as means  SD (baseline charac-
teristics) and means  SEM. U-LFABP
and UACR are given as medians (inter-
quartile range [IQR]). All comparisons
between groups of normally or log-
normally distributed parameters were
performed with a one-way ANOVA, and
ordinal data were compared using a
Kruskall-Wallis and a Mann-Whitney U
test. Changes in variables between visits
during the intervention study are ex-
pressed as mean differences (95% CI).
Comparisons of log-U-LFABP between
each treatment period were performed
using linear mixed models. The adapted
model was one with ﬁxed effects of treat-
mentlevel,visit,andcarryover(i.e.,treat-
ment level in the previous period) and a
random effect of person included to ac-
count for the person independence in
data. Linear regression analysis was used
to analyze for correlations between the
change from baseline in U-LFABP based
on differences in log-transformed values
and changes in UAER, ambulatory blood
pressure, and eGFR, respectively. P 
0.05 was considered signiﬁcant (two-
tailed test). Data were evaluated using
SPSS (version 14.0; SPSS, Chicago, IL).
RESULTS
Cross-sectional study
The clinical characteristics of the patients
are shown in Table 1. The patients were
well matched regarding the duration of
diabetes and sex. Patients with nor-
moalbuminuria and microalbuminuria
were slightly older than control subjects
and patients with macroalbuminuria.
We found a signiﬁcant difference in
systolic blood pressure among the groups
(P  0.009) because of a difference be-
tween control subjects and patients with
microalbuminuria (P  0.017) and mac-
roalbuminuria (P  0.001). Diastolic
blood pressure was signiﬁcantly higher in
control subjects, whereas there was no
difference among diabetic groups. eGFR
was signiﬁcantly lower in the macroalbu-
minuric group than in all other groups.
The signiﬁcant difference in serum creat-
inine was due to differences between the
macroalbuminuric group and all other
groups.
U-LFABP and urinary albumin
excretion
U-LFABP levels are shown in Table 1 and
illustrated in Fig. 1. U-LFABP ratios were
signiﬁcantly higher in the normoalbu-
minuric group versus the control group
(median 2.6 [IQR 1.3–4.1] vs. 1.9 [0.8–
3.0] g/g creatinine, P  0.02) and in-
creased with increasing levels of
albuminuria (microalbuminuric group
4.2 [1.8–8.3] g/g creatinine and mac-
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g/g creatinine, P  0.05 for all
comparisons.
U-LFABP correlated with UACR (R
2 
0.54, P  0.001) in the combined group
of all diabetic patients. In the normoalbu-
minuric group, there was also a signiﬁ-
cant but weak association between UACR
and U-LFABP (R
2  0.07, P  0.04).
In patients with macroalbuminuria,
U-LFABP levels correlated with UACR
(R
2  0.50, P  0.001) and eGFR (R
2 
0.34, P  0.001). When adjusted for
eGFR, there was still a signiﬁcant differ-
ence in U-LFABP for comparisons be-
tween patients with macroalbuminuria
and the other groups (P  0.01).
Therewasasigniﬁcantcorrelationbe-
tween U-LFABP and systolic blood pres-
sure (R
2  0.07, P  0.001). However,
this may be explained by the association
between U-LFABP and renal function be-
cause it disappeared after adjustment for
eGFR and UACR. There were no signiﬁ-
cant associations between U-LFABP and
sex, age, BMI, diastolic blood pressure,
cholesterol, or A1C.
Effect of ACE inhibition on
U-LFABP: intervention study
A total of 56 patients were randomly as-
signed in the study, and 49 patients com-
pletedthestudy.Onepatientdidnothave
U-LFABP measured at baseline; results
are given for the remaining 48.
Age at baseline was (mean  SD)
50  10 years and the duration of diabe-
teswas3310years.BaselineUAERwas
(geometric mean) 365 mg/24 h (95% CI
240–554). Baseline GFR (
51Cr-EDTA)
was 73  28 ml/min per 1.73 m
2.
All doses of lisinopril signiﬁcantly re-
duced UAER, U-LFABP, and arterial
blood pressure compared with baseline
(Table 2). At baseline, U-LFABP was me-
dian 12.69 g/24 h (IQR 3.88–49.82).
Reductions from baseline in U-LFABP
were 43% (95% CI 15–62), 46% (19–
64), and 40% (11–60) with increasing
doses of lisinopril (no signiﬁcant differ-
ence between doses). The reduction in U-
LFABPwasassociatedwiththechangesin
24-h systolic ambulatory blood pressure
(R
2  0.22, P  0.01) (similar for dia-
stolic ambulatory blood pressure) and
UAER (R
2  0.38, P  0.001) but not
with changes in eGFR. (Data are given for
change from baseline to 40 mg of lisino-
pril, which gave the largest response, but
the same results were found for the other
doses of lisinopril.) The decline in U-
LFABP was still signiﬁcant when adjusted
for the decline in UAER and for 24-h sys-
tolic blood pressure (P  0.011).
CONCLUSIONS — In our cross-
sectional study, we have shown that the
marker of tubulointerstitial damage, U-
LFABP, is elevated in type 1 diabetic pa-
tientscomparedwithnondiabetichealthy
control subjects. In addition, we have
shown that U-LFABP is further increased
in type 1 diabetic patients with micro-
and macroalbuminuria, reﬂecting in-
creased tubular damage with increasing
levels of albuminuria. There were no sig-
niﬁcant correlations between U-LFABP
and sex, age, or A1C.
In our randomized, double-masked
crossover study, ACE inhibition with lis-
inopril reduced U-LFABP. There was no
signiﬁcant difference in effect between
dosesoflisinoprilfrom20to60mgdaily.
Figure 1—U-LFABP in control group and three diabetic groups with different levels of
albuminuria.
Table1—Clinicaldataofcontrolgroupandtype1diabeticpatientsdifferentiatedaccordingtothelevelofalbuminuriaincross-sectionalstudy
Control
group Normoalbuminuria Microalbuminuria Macroalbuminuria P
n (male/female) 57 (37/20) 58 (30/28) 45 (24/21) 45 (27/18) 0.273
Age (years) 51  11.0 56  10.8 54  11.1 49  9.3 0.004
Diabetes duration (years) — 37  11 35  11 34  11 0.411
Systolic blood pressure (mmHg) 132  16 138  21 142  23 145  19 0.009
Diastolic blood pressure (mmHg) 81  11 75  11 74  12 78  10 0.002
A1C (%) 5.5  0.3 8.2  1.1 8.8  1.2 8.8  1.1 0.001
eGFR (ml/min per 1.73m
2) 70.5  9.6 70.3  10.3 71.0  13.3 48.7  19.2 0.001
Creatinine (mol/l)* 95 (73–146) 91 (69–121) 89 (70–143) 127 (84–144) 0.001
UACR (mg/g)† 2 (1–5) 5 (3–9) 27 (11–68) 461 (173–1,172) —
U-LFABP (g/g creatinine)† 1.9 (0.8–3.0) 2.6 (1.3–4.1) 4.2 (1.8–8.3) 71.2 (8.1–123.4) 0.05
Data are means  SD, *median (range), or †median (IQR). P value refers to allover difference between groups (ANOVA).
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tes were cross-sectional studies on U-
LFABPintype2diabeticpatients.Suzukiet
al.(14)performedacross-sectionalstudyin
356 adult type 2 diabetic patients. They di-
vided the patients into four groups: nor-
moalbuminuric, microalbuminuric,
macroalbuminuric,andrenalfailure,butno
control group was included. They reported
a signiﬁcant association between the stage
of diabetic nephropathy and U-LFABP, al-
though no signiﬁcant difference between
the normoalbuminuric and microalbumin-
uric groups was seen.
The results from our cross-sectional
studyshowthatpatientswithnormoalbu-
minuria and type 1 diabetes had higher
U-LFABP than the healthy control sub-
jects (Table 1). The normoalbuminuric
group had a signiﬁcantly higher level of
albuminuriathanthehealthycontrolsub-
jects, but even with adjustment for this
result, there was still a signiﬁcant differ-
enceinU-LFABPbetweenthetwogroups
(P  0.014). One possible explanation is
that having diabetes elevates U-LFABP.
However, this possibility is not likely be-
cause U-LFABP is not correlated with
A1C. Another hypothesis is that some of
the patients in the normoalbuminuric
group had higher levels of U-LFABP as a
predictor of future development of mi-
croalbuminuria and diabetic nephropa-
thy. The signiﬁcant association between
UACR and U-LFABP in the normoalbu-
minuric group also indicated this. How-
ever, to test this hypothesis we need
prospective follow-up studies in nor-
moalbuminuric type 1 diabetic patients.
We also saw that with increasing lev-
els of albuminuria, from normoalbumin-
uria to microalbuminuria and
macroalbuminuria, U-LFABP is increas-
ing. Part of this association can be ex-
plained by the transport with albumin of
fatty acids to the proximal tubules. Here
the fatty acids are absorbed into the prox-
imal tubular cells, where the role of
LFABPistotransportthefattyacidstothe
mitochondria. Therefore, when albumin-
uria increases, the LFABP gene is upregu-
lated and more LFABP is excreted into
the urine (15). U-LFABP is also elevated
independently of albuminuria because of
increased tubular production due to tu-
bular hypoxia and oxidative stress (16),
which is seen in diabetes (17). Our study
is cross-sectional, and therefore we can-
not draw conclusions on the time per-
spective between elevation in U-LFABP
and development of nephropathy. How-
ever, from earlier studies in nondiabetic
chronic renal disease, the potential of U-
LFABP as an early predictor of nephropa-
thy is supported. Kamijo et al. (18)
performed a multicenter observational
trial in 48 patients with nondiabetic
chronic kidney disease. Retrospectively,
they divided the patients into progressors
and nonprogressors in their chronic kid-
ney disease based on changes in creati-
nineclearanceduring1yearoffollow-up.
They found that U-LFABP had a higher
sensitivity (94%) than urinary albumin
(69%) but a lower speciﬁcity (63%) than
urinary albumin (94%) in predicting pro-
gression in chronic kidney disease.
U-LFABP is different from other sug-
gested biomarkers, e.g., 1- and 	2-
microglobulins: U-LFABP is produced in
the tubular cells, whereas 1- and 	2-
microglobulins are freely ﬁltered through
the glomerular basement membrane.
Duringpoorglycemiccontrol,urinaryex-
cretion of 	2-microglobulin is increased
(19); this is a result of a lack of reabsorp-
tion in the damaged tubular cell (20,21).
	2-Microglobulin is unstable at low pH,
causing an underestimate of the tubular
damage (22).
In our randomized, crossover study,
we saw that 2 months of ACE inhibition
reduces U-LFABP by 
40%. There was
no signiﬁcant difference in the decline in
U-LFABP among doses of lisinopril, sug-
gesting an optimal effect with 20 mg lis-
inopril daily, which was in contrast to the
increased decline in UAER when doses
of lisinopril were increased from 20 to
40 mg.
We observed that the decrease in U-
LFABP is associated with a decrease in al-
buminuria, but the relatively weak
association (R
2  0.38, P  0.001) sup-
ports the fact that the decline in U-LFABP
is not only explained by reduced albu-
minuria but also suggests, as mentioned
earlier, that the reduction also reﬂects re-
duced tubular damage. The decrease in
U-LFABP indicates that the tubular dam-
age and upregulation of the U-LFABP
gene are reversible.
Ourﬁndingisinaccordancewithear-
lier studies in type 2 diabetic patients
(23),whichshowedasigniﬁcantdecrease
in U-LFABP when these patients were
treatedwithanangiotensinIIreceptoran-
tagonist. Experimental studies in diabetic
rats have shown that renin-angiotensin-
aldosterone system blockade reduces an-
tiapoptotic factors (24) and that oxidative
stress in tubular cells is reduced and
chronichypoxiaiscorrectedindependent
ofthebloodpressure–loweringeffect(25)
and thereby preserves tubular function.
In summary, an early and progressive
rise in tubulointerstitial damage as re-
ﬂected by increased U-LFABP levels oc-
curs in type 1 diabetic patients and is
associated with albuminuria. Further-
more, ACE inhibition reduces the tubular
and glomerular damage and dysfunction.
Our studies indicate that U-LFABP is a
new marker of tubular damage and a po-
tential supplement to the glomerular
damage marker albuminuria for progno-
sis,diagnosis,andtreatmentofkidneyin-
jury, although further longitudinal
studies are needed.
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